The Practical Cardiology™ Cholesterol Disorders clinical resource center offers the latest information from the field of lipidology. With hypercholesterolemia and hyperlipidemia representing a crucial aspect of risk management, this page will be a hub for information related to the latest in cholesterol management and dyslipidemia, including articles, videos, and podcasts.
December 14, 2022
An analysis of data from the MESA study sheds further light on associations of lipoprotein(a) and cardiovascular risk among a primary prevention cohort.
December 09, 2022
Data from an analysis of patients in Denmark provides an overview of the effects of statin therapy on risk of intracerebral hemorrhage, with insights into how this benefit may vary based on the location of the intracerebral hemorrhage.
December 07, 2022
Almost 3 years after approval, Esperion's announcement of positive results from the CLEAR Outcomes trial indicate bempedoic acid is the first oral non-statin therapy to meet the MACE-4 primary endpoint included in the outcomes trial of the ATP citrate lyase inhibitor.
December 01, 2022
A cluster randomized trial from Penn Medicine's Nudge Unit provides insight into the effects of "nudges" in primary care settings for improving the prescription of statins.
November 26, 2022
The November 2022 cardiology month in review features the top content from AHA Scientific Sessions 2022, new data related to use of direct oral anticoagulation, and an FDA warning to companies over violations of the FD&C Act.
November 24, 2022
An analysis of statin initiators within the VITAL trial provides insight into the impact of vitamin D supplementation on the incidence of statin-associated muscle symptoms and statin discontinuation among participants in the trial.
November 22, 2022
New research comparing use of lipid biomarkers for predicitng coronary heart disease suggests HDL-C may not provide the cardioprotective benefits purported in previous data.
November 10, 2022
A 10,000-person study provides insight into the feasibility and effectiveness of participation an entirely remote hypertension and lipid management program in a diverse health care network.
November 08, 2022
Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.
November 06, 2022
Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.